Angiex

2 undisclosed programs RD undisclosed

Angiex, based in Cambridge, MA, was founded in 2015 by Harold Dvorak, Paul Jaminet, and Shou-Ching Jaminet, leading scientific experts in angiogenesis, vascular biology, and oncology. They utilize their Nuclear Delivery Platform to deliver therapeutics to tumor cells and tumor vascular endothelial cells, preventing their lethality. This platform has allowed them to produce a portfolio of Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) to treat cancer.

Jobs: